prikaz prve stranice dokumenta Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?
  Preuzmi
PDF 2.77 MB
Znanstveni rad - Izvorni znanstveni rad
Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?
Human Vaccines & Immunotherapeutics, 20 (2024), 1; 2301186. https://doi.org/10.1080/21645515.2023.2301186
Tzanakaki, Georgina; Cabrnochová, Hana; Delić, Snežana; Draganescu, Anca; Hilfanova, Anna; Onozó, Beáta; Pokorn, Marko; Skoczyńska, Anna; Tešović, Goran

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Tzanakaki, G., Cabrnochová, H., Delić, S., Draganescu, A., Hilfanova, A., Onozó, B. ... Tešović, G. (2024). Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?. Human Vaccines & Immunotherapeutics, 20. (1). doi: 10.1080/21645515.2023.2301186

Tzanakaki, Georgina, et al. "Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?." Human Vaccines & Immunotherapeutics, vol. 20, br. 1, 2024. https://doi.org/10.1080/21645515.2023.2301186

Tzanakaki, Georgina, Hana Cabrnochová, Snežana Delić, Anca Draganescu, Anna Hilfanova, Beáta Onozó, Marko Pokorn, Anna Skoczyńska i Goran Tešović. "Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?." Human Vaccines & Immunotherapeutics 20, br. 1 (2024). https://doi.org/10.1080/21645515.2023.2301186

Tzanakaki, G., et al. (2024) 'Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?', Human Vaccines & Immunotherapeutics, 20(1). doi: 10.1080/21645515.2023.2301186

Tzanakaki G, Cabrnochová H, Delić S, Draganescu A, Hilfanova A, Onozó B, i sur.. Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?. Human Vaccines & Immunotherapeutics [Internet]. 04.01.2024. [pristupljeno 24.12.2024.];20(1). doi: 10.1080/21645515.2023.2301186

G. Tzanakaki, et al., "Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?", Human Vaccines & Immunotherapeutics, vol. 20, br. 1, Siječanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:912176. [Citirano: 24.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:912176
Podaci o radu
Naslov (engleski)Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?
AutorGeorgina Tzanakaki
AutorHana Cabrnochová
AutorSnežana Delić
AutorAnca Draganescu
AutorAnna Hilfanova
AutorBeáta Onozó
AutorMarko Pokorn
AutorAnna Skoczyńska
AutorGoran Tešović
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INFEKTOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Sažetak (engleski)
Invasive meningococcal disease (IMD) is an acute life-threatening infection caused by the gram-negative bacterium, Neisseria meningitidis. Globally, there are approximately half a million cases of IMD each year, with incidence varying across geographical regions. Vaccination has proven to be successful against IMD, as part of controlling outbreaks, and when incorporated into national immunization programs. The South-Eastern Europe Meningococcal Advocacy Group (including representatives from Croatia, the Czech Republic, Greece, Hungary, Poland, Romania, Serbia, Slovenia and Ukraine) was formed in order to discuss the potential challenges of IMD faced in the region. The incidence of IMD across Europe has been relatively low over the past decade; of the countries that came together for the South-Eastern Meningococcal Advocacy Group, the notification rates were lower than the European average for some country. The age distribution of IMD cases was highest in infants and children, and most countries also had a further peak in adolescents and young adults. Across the nine included countries between 2010 and 2020, the largest contributors to IMD were serogroups B and C; however, each individual country had distinct patterns for serogroup distribution. Along with the variations in epidemiology of IMD between the included countries, vaccination policies also differ.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaHuman Vaccines & Immunotherapeutics
Brojčani podacivol. 20, br. 1, 2301186
p-ISSN2164-5515
e-ISSN2164-554X
DOIhttps://doi.org/10.1080/21645515.2023.2301186
URN:NBNurn:nbn:hr:105:912176
Datum objave publikacije2024-01-04
URL dokumentahttps://www.tandfonline.com/doi/full/10.1080/21645515.2023.2301186
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2024-12-12 11:49:32